Evidence Vault

The global landscape for clinical evidence is undergoing a fundamental shift as regulatory agencies and payers move away from static clinical trial results toward continuous post-market surveillance streams. This transition is driven by the increasing necessity for longitudinal data to support drug and device approvals, particularly in an environment where traditional single-arm trials face higher levels of scrutiny. The Rising Mandate for Real-World Evidence Regulatory adoption of Real-World Evidence (RWE) has accelerated significantly over the last several years. The proportion of FDA approvals containing RWE increased from approximately 5% to 10% in 2020 to nearly 50% by 2024. This shift is not merely a change in preference but a structural requirement; regulatory agencies are now frequently rejecting single-arm trials that lack synthetic control arms derived from longitudinal health records. The economic implications of this shift are reflected in the projected growth of the RWE solutions market, which was estimated at $2.6 billion in 2025 and is expected to reach $12 billion by 2035. Furthermore, cloud-based deployment models now capture approximately 64% of the market, as they provide the elastic computing power and pricing models required for large-scale data analysis. The Circle Dataset Intervention: Federated Data Capture and Regulatory Readiness A primary challenge in meeting these new regulatory standards is the difficulty of accessing verifiable, high-quality longitudinal data that remains compliant with global privacy and residency requirements. Circle Datasets address this through the Federated Healthcare Data Capture model. A key feature of this model is that clinical data remains at the primary point of care—ensuring compliance with data residency laws—while being accessible for analysis via secure, cloud-based infrastructure. This architecture ensures that the resulting datasets are verifiable, unambiguously owned, and "regulatory-ready". This provides drug and device manufacturers with the synthetic control arms now essential for securing FDA approval. By adopting this prospective architecture, health systems can transform their data from a liability into a capital asset that benefits providers, patients, and payers alike.

The primary bottleneck in the clinical translation process is the resource-intensive nature of traditional systematic reviews. These reviews, which form the definitive basis for medical textbooks and clinical guidelines, typically require years to complete. This delay ensures that by the time evidence is formally synthesized and reaches the point of care, the underlying data may already be outdated. This linear, non-collaborative workflow is a fundamental driver of the 17-year evidence-to-practice gap. The Challenges of Manual Synthesis Manual literature screening and data extraction are limited by human capacity and are prone to significant sensitivity gaps. The volume of biomedical research is now so vast that updating even a small subset of clinical reviews can involve screening hundreds of thousands of citations. • Temporal Lag: The average duration to move from a publication to its inclusion in a systematic review or textbook is 6.3 years. • Human Error: Human reviewers typically achieve approximately 82% sensitivity in literature screening, leaving a 18% margin for missed evidence. • Resource Exhaustion: Systematic reviews are often delayed or left un-updated due to the extreme resource intensity required for manual synthesis. The Circle Dataset Intervention: Structured AI Orchestration A primary feature of Circle Datasets is the production of structured, standardized outputs specifically designed for seamless integration into AI-assisted evidence synthesis. By utilizing protocol-driven, deterministic data rather than unstructured electronic health record (EHR) scrapes, the platform provides the high-quality foundation necessary for Large Language Models (LLMs) to perform synthesis without the risk of hallucination. This integration enables the technical reality of Evidence-as-a-Service: • Synthesis Velocity: LLM-based approaches, such as the "otto-SR" system, have demonstrated the ability to update 12 Cochrane reviews—analyzing 146,276 citations—in under 48 hours. • Superior Precision: Automated systems have demonstrated a 97% sensitivity in literature screening, exceeding human performance by 15%. • Point-of-Care Delivery: Because Circle Datasets are built on interoperable mappings (such as FHIR and USCDI), the synthesized evidence can be delivered as context-aware updates directly into the EHR at the point of care. This architectural shift transforms clinical evidence from a static, retrospective document into a dynamic infrastructure that continuously updates the medical knowledge base in near-real-time .

In the legacy healthcare data economy, patients are often viewed as passive subjects whose information is extracted and monetized by third-party intermediaries without their explicit consent or financial benefit . This extraction model erodes trust and fails to acknowledge that personal healthcare data are "rights-laden emanations of the person" that should be protected as a human right. Furthermore, patients face significant financial pressure, with high out-of-pocket costs remaining a primary concern for 71% of consumers. The Crisis of Trust and Privacy As younger generations become more digitally proactive—with 75% to 80% using health technology monthly—there is a growing demand for a "digital social contract" grounded in dignity and participation . The current centralized storage of medical records increases the risk of large-scale data breaches and identity theft. Patients frequently have no visibility into how their data is used or whether it contributes to clinical practices that are actually effective for their specific conditions. The Circle Dataset Intervention: Self-Sovereign Identity and Data Dividends A primary feature of Circle Datasets is the integration of Self-Sovereign Identity (SSI) and the Circle Health Coin to return control and value to the patient.

Health insurance payers are currently facing significant upward pressure from rising medical costs, with trends projected at 8% to 9% through the end of 2026. A critical metric in this environment is the Medical Loss Ratio (MLR)—the specific percentage of premium income dedicated to medical claims. To manage this ratio effectively, payers must distinguish between clinical interventions that demonstrate genuine efficacy in diverse populations and those that only show results in highly controlled environments. The Limitation of Idealized Clinical Trials A primary challenge for payers is the "efficacy gap"—the discrepancy between how a drug or procedure performs in an idealized clinical trial versus how it performs in the general patient population. Traditional data sources often lack the granularity to identify why certain high-cost therapies fail to meet clinical markers in real-world settings. A primary feature of Circle Datasets is the provision of deterministic longitudinal data, which allows payers to transition from reactive claims processing to proactive risk management. By tracking a patient’s journey through a standardized protocol, Circle Datasets provide the verifiable evidence needed to negotiate outcome-based agreements with manufacturers. For example, in the management of high-cost specialty drugs, payers can use the deterministic evidence within a Circle Dataset to trigger rebates if a drug fails to meet specific clinical markers, such as HbA1C levels. Furthermore, the integration of structured Circle Datasets into AI-driven analysis can reduce fraud and waste by up to 50% by ensuring that all risk-adjustment documentation is fully supported by protocol-driven clinical evidence. This structural shift allows payers to stabilize their MLR by eliminating spending on ineffective therapies and ensuring high-precision risk adjustment.

For healthcare providers, the process of clinical data collection has historically functioned as a significant administrative burden with no direct financial return. Under legacy models, clinicians often enter data into electronic health records (EHR) only for that information to be siphoned by third-party brokers who monetize it without compensating the source . Furthermore, failure to meet evolving quality reporting standards can lead to severe financial consequences, including negative payment adjustments from the Centers for Medicare & Medicaid Services (CMS). The Burden of Quality Compliance Modern reimbursement is increasingly tied to value-based metrics. Providers who fail to satisfy CMS quality requirements—such as those under the Merit-based Incentive Payment System (MIPS) or Hospital Value-Based Purchasing—face negative payment adjustments of up to 9%. Conversely, those who demonstrate high-quality outcomes through standardized data are eligible for positive bonuses. However, the manual effort required to aggregate and verify this data often offsets the potential financial gains. The Circle Dataset Intervention: Direct License Revenue A primary feature of Circle Datasets is the transformation of data collection from an administrative cost into a diversified revenue stream . By utilizing the Split-IP model, participating physicians maintain majority ownership of the data they generate. When these datasets are licensed for regulatory, scientific, or commercial use, the platform contractually assigns the majority share of the licensing fees back to the contributing providers. This creates a profit center independent of fee-for-service reimbursement. Additionally, because the platform utilizes a standardized Observational Protocol, it automatically generates the deterministic evidence required to satisfy CMS quality incentives, enabling providers to secure positive payment adjustments while reducing the internal labor costs associated with registry participation

The traditional healthcare data economy is built upon an extraction model where third-party brokers monetize provider and patient information through "silent" de-identification clauses. This model frequently compromises patient privacy and provides no financial return to the original data sources. Furthermore, treating healthcare information as a neutral commodity rather than a rights-laden asset erodes trust between stakeholders and contributes to the misalignment of financial incentives that characterizes the modern evidence gap. The Data Brokerage Conflict Under the legacy framework, data is often siphoned away from the point of care without the explicit benefit or control of the clinicians and patients who generated it. This extraction process creates several systemic challenges